Silviu Sbiera

List of Publications by Year
in descending order

73 papers	4,942 citations	147801 31 h-index	95266 68 g-index
75 all docs	75 docs citations	75 times ranked	5404 citing authors

#	Article	IF	Citations
1	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
2	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
3	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
4	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nature Genetics, 2015, 47, 31-38.	21.4	450
5	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. New England Journal of Medicine, 2014, 370, 1019-1028.	27.0	355
6	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E161-E171.	3.6	196
7	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	2.8	153
8	Î²-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. Clinical Cancer Research, 2011, 17, 328-336.	7.0	128
9	<scp>FATE</scp> 1 antagonizes calciumâ€•and drugâ€•induced apoptosis by uncoupling <scp>ER</scp> and mitochondria. EMBO Reports, 2016, 17, 1264-1280.	4.5	102
10	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. European Journal of Endocrinology, 2016, 174, 363-372.	3.7	100
11	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	3.6	92
12	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	3.6	79
13	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	3.6	65
14	Driver mutations in USP8 wild-type Cushingâ€™s disease. Neuro-Oncology, 2019, 21, 1273-1283.	1.2	65
15	Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clinical Cancer Research, 2012, 18, 3452-3461.	7.0	64
16	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer, 2009, 16, 907-918.	3.1	63
17	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
18	Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence?. PLoS ONE, 2013, 8, e73959.	2.5	58

#	Article	IF	Citations
19	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	7.1	57
20	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 2010, 23, 1596-1604.	5.5	46
21	Influence of Short-Term Glucocorticoid Therapy on Regulatory T Cells In Vivo. PLoS ONE, 2011, 6, e24345.	2.5	46
22	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	3.6	44
23	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. Science Advances, 2021, 7, .	10.3	42
24	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	2.5	41
25	Association of Human Polyomavirus JC with Peripheral Blood of Immunoimpaired and Healthy Individuals. Journal of NeuroVirology, 2003, 9, 81-87.	2.1	39
26	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death and Disease, 2020, 11, 192.	6.3	39
27	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2251-E2260.	3.6	38
28	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. European Journal of Endocrinology, 2014, 171, R1-R11.	3.7	37
29	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. Endocrinology, 2018, 159, 1511-1524.	2.8	37
30	Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Science Signaling, 2017, 10, .	3.6	35
31	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	3.6	33
32	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. Endocrinology, 2019, 160, 447-459.	2.8	32
33	Corticotroph tumor progression after bilateral adrenalectomy (Nelsonâ€™s syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	3.7	32
34	Single Nucleotide Polymorphism Microarray Analysis in Cortisol-Secreting Adrenocortical Adenomas Identifies New Candidate Genes and Pathways. Neoplasia, 2012, 14, 206-IN13.	5.3	31
35	Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Frontiers in Endocrinology, 2011, 2, 27.	3.5	29
36	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2535-2546.	3.6	29

#	Article	IF	Citations
37	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	3.1	27
38	The New Genetic Landscape of Cushingâ€™s Disease: Deubiquitinases in the Spotlight. Cancers, 2019, 11, 1761.	3.7	27
39	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget, 2017, 8, 9323-9338.	1.8	27
40	The New Molecular Landscape of Cushing's Disease. Trends in Endocrinology and Metabolism, 2015, 26, 573-583.	7.1	26
41	Expression of <scp>LIN</scp>28 and its regulatory micro<scp>RNA</scp>s in adult adrenocortical cancer. Clinical Endocrinology, 2015, 82, 481-488.	2.4	25
42	The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition. Molecular and Cellular Endocrinology, 2016, 428, 68-81.	3.2	25
43	Topoisomerase 2Î± and thymidylate synthase expression in adrenocortical cancer. Endocrine-Related Cancer, 2017, 24, 319-327.	3.1	24
44	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	3.6	24
45	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 219.	3.5	23
46	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	3.7	23
47	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. European Journal of Endocrinology, 2016, 174, 343-353.	3.7	20
48	A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. European Journal of Endocrinology, 2021, 184, 823-835.	3.7	20
49	Survivin in Adrenocortical Tumors - Pathophysiological Implications and Therapeutic Potential. Hormone and Metabolic Research, 2013, 45, 137-146.	1.5	19
50	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. Clinical Chemistry, 2019, 65, 1276-1286.	3.2	19
51	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.	3.6	18
52	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. Scientific Reports, 2017, 7, 49.	3.3	17
53	Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. Cancers, 2020, 12, 724.	3.7	16
54	Dendritic Cell Based Immunotherapy - A Promising Therapeutic Approach for Endocrine Malignancies. Hormone and Metabolic Research, 2008, 40, 89-98.	1.5	15

#	Article	IF	Citations
55	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. European Journal of Endocrinology, 2018, 178, 181-188.	3.7	15
56	Steroidogenesis in the NCI-H295 Cell Line Model is Strongly Affected By Culture Conditions and Substrain. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 672-680.	1.2	14
57	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers, 2020, 12, 689.	3.7	14
58	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. Hormones and Cancer, 2016, 7, 345-355.	4.9	12
59	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. Cancers, 2021, 13, 4671.	3.7	12
60	Circulating microRNA Expression in Cushingâ€™s Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	3.5	11
61	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	10
62	Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. Hormones and Cancer, 2015, 6, 225-236.	4.9	8
63	Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. Molecular and Cellular Endocrinology, 2019, 480, 36-41.	3.2	8
64	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. PLoS ONE, 2016, 11, e0169009.	2.5	7
65	Characterization of Adrenal miRNA-Based Dysregulations in Cushingâ€™s Syndrome. International Journal of Molecular Sciences, 2022, 23, 7676.	4.1	7
66	Subtype-specific pattern of white blood cell differential in endogenous hypercortisolism. European Journal of Endocrinology, 2022, 187, 439-449.	3.7	7
67	Association of Human Polyomavirus JC with Peripheral Blood of Immunoimpaired and Healthy Individuals. Journal of NeuroVirology, 2003, 9, 81-87.	2.1	6
68	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. Endocrine, 2022, 77, 411-418.	2.3	6
69	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. Cancers, 2021, 13, 1736.	3.7	5
70	Case Report: Consecutive Adrenal Cushingâ€™s Syndrome and Cushingâ€™s Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. Frontiers in Endocrinology, 2021, 12, 731579.	3.5	5
71	SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?. International Journal of Molecular Sciences, 2022, 23, 3726.	4.1	5
72	PKA CÎ± subunit mutation triggers caspase-dependent RIIÎ² subunit degradation via Ser ¹¹⁴ phosphorylation. Science Advances, 2021, 7, .	10.3	4

#	Article	IF	Citations
73	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Frontiers in Endocrinology, 2021, 12, 795116.	3.5	2